{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:22:07Z","timestamp":1740122527067,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100007225","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","award":["MOST 108-2314-B-002-118-MY3"],"award-info":[{"award-number":["MOST 108-2314-B-002-118-MY3"]}],"id":[{"id":"10.13039\/100007225","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-023-02887-7","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T13:01:55Z","timestamp":1695387715000},"page":"578-587","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Risk of thromboembolic events associated with different multiple myeloma regimens in Taiwan: a nested case-control study"],"prefix":"10.1007","volume":"56","author":[{"given":"Mei-Tsen","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Tsung","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huai-Hsuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Jone","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bor-Sheng","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1660-9120","authenticated-orcid":false,"given":"Fei-Yuan","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,22]]},"reference":[{"key":"2887_CR1","volume-title":"Harrison\u2019s principles of Internal Medicine, 20e","author":"NC Munshi","year":"2018","unstructured":"Munshi NC, Longo DL, Anderson KC (2018) Plasma Cell Disorders. In: Jameson JL, Fauci AS, Kasper DL et al (eds) Harrison\u2019s principles of Internal Medicine, 20e. McGraw-Hill Education, New York, NY"},{"key":"2887_CR2","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal S, Mehta J, Desikan R et al (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565\u20131571","journal-title":"N Engl J Med"},{"key":"2887_CR3","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","volume":"24","author":"SV Rajkumar","year":"2006","unstructured":"Rajkumar SV, Blood E, Vesole D et al (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24:431\u2013436","journal-title":"J Clin Oncol"},{"key":"2887_CR4","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","volume":"357","author":"M Dimopoulos","year":"2007","unstructured":"Dimopoulos M, Spencer A, Attal M et al (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357:2123\u20132132","journal-title":"N Engl J Med"},{"key":"2887_CR5","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa1402551","volume":"371","author":"L Benboubker","year":"2014","unstructured":"Benboubker L, Dimopoulos MA, Dispenzieri A et al (2014) Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 371:906\u2013917","journal-title":"N Engl J Med"},{"key":"2887_CR6","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW et al (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487\u20132498","journal-title":"N Engl J Med"},{"key":"2887_CR7","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.clml.2017.06.030","volume":"17","author":"DW Sherbenou","year":"2017","unstructured":"Sherbenou DW, Mark TM, Forsberg P (2017) Monoclonal antibodies in multiple myeloma: a new wave of the future. Clin Lymphoma Myeloma Leuk 17:545\u2013554","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2887_CR8","first-page":"4991","volume":"115","author":"SY Kristinsson","year":"2010","unstructured":"Kristinsson SY, Pfeiffer RM, Bj\u00f6rkholm M et al (2010) Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood The Journal of the American Society of Hematology 115:4991\u20134998","journal-title":"Blood The Journal of the American Society of Hematology"},{"key":"2887_CR9","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.thromres.2012.11.014","volume":"131","author":"A Kato","year":"2013","unstructured":"Kato A, Takano H, Ichikawa A et al (2013) A retrospective cohort study of venous thromboembolism (VTE) in 1035 japanese myeloma patients treated with thalidomide; lower incidence without statistically significant association between specific risk factors and development of VTE and effects of thromboprophylaxis with aspirin and warfarin. Thromb Res 131:140\u2013144","journal-title":"Thromb Res"},{"key":"2887_CR10","first-page":"1091","volume":"136","author":"CA Bradbury","year":"2020","unstructured":"Bradbury CA, Craig Z, Cook G et al (2020) Thrombosis in patients with myeloma treated in the myeloma IX and myeloma XI phase 3 randomized controlled trials. Blood. J Am Soc Hematol 136:1091\u20131104","journal-title":"J Am Soc Hematol"},{"key":"2887_CR11","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/rth2.12411","volume":"4","author":"MW Schoen","year":"2020","unstructured":"Schoen MW, Carson KR, Luo S et al (2020) Venous thromboembolism in multiple myeloma is associated with increased mortality. Res Pract Thromb haemostasis 4:1203\u20131210","journal-title":"Res Pract Thromb haemostasis"},{"key":"2887_CR12","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1002\/cncr.32682","volume":"126","author":"R Chakraborty","year":"2020","unstructured":"Chakraborty R, Bin Riaz I, Malik SU et al (2020) Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: a systematic review and meta\u2010analysis. Cancer 126:1640\u20131650","journal-title":"Cancer"},{"key":"2887_CR13","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/j.1365-2141.2004.05078.x","volume":"126","author":"M Zangari","year":"2004","unstructured":"Zangari M, Barlogie B, Anaissie E et al (2004) Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 126:715\u2013721","journal-title":"Br J Haematol"},{"key":"2887_CR14","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1002\/ajh.25603","volume":"94","author":"KM Sanfilippo","year":"2019","unstructured":"Sanfilippo KM, Luo S, Wang TF et al (2019) Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. Am J Hematol 94:1176\u20131184","journal-title":"Am J Hematol"},{"key":"2887_CR15","doi-asserted-by":"publisher","first-page":"840","DOI":"10.6004\/jnccn.2018.7273","volume":"17","author":"A Li","year":"2019","unstructured":"Li A, Wu Q, Luo S et al (2019) Derivation and validation of a risk assessment model for immunomodulatory drug\u2013associated thrombosis among patients with multiple myeloma. J Natl Compr Canc Netw 17:840\u2013847","journal-title":"J Natl Compr Canc Netw"},{"key":"2887_CR16","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1538-7836.2011.04215.x","volume":"9","author":"M Carrier","year":"2011","unstructured":"Carrier M, Le Gal G, Tay J et al (2011) Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost 9:653\u2013663","journal-title":"J Thromb Haemost"},{"key":"2887_CR17","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa070596","volume":"357","author":"DM Weber","year":"2007","unstructured":"Weber DM, Chen C, Niesvizky R et al (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357:2133\u20132142","journal-title":"N Engl J Med"},{"key":"2887_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1200\/GO.20.00228","volume":"7","author":"SK Bondili","year":"2021","unstructured":"Bondili SK, Bagal B, Zawar A et al (2021) Real-world outcomes with generic pomalidomide in relapsed refractory multiple myeloma\u2014experience from a Tertiary Care Cancer Center. JCO Global Oncology 7:361\u2013367","journal-title":"JCO Global Oncology"},{"key":"2887_CR19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00277-019-03860-2","volume":"99","author":"A Li","year":"2020","unstructured":"Li A, Wu Q, Warnick G et al (2020) The incidence of thromboembolism for lenalidomide versus thalidomide in older patients with newly diagnosed multiple myeloma. Ann Hematol 99:121\u2013126","journal-title":"Ann Hematol"},{"key":"2887_CR20","first-page":"497","volume":"128","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Palumbo A, Corradini P et al (2016) Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood The Journal of the American Society of Hematology 128:497\u2013503","journal-title":"Blood The Journal of the American Society of Hematology"},{"key":"2887_CR21","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/bjh.16213","volume":"188","author":"DS Siegel","year":"2020","unstructured":"Siegel DS, Schiller GJ, Song KW et al (2020) Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure. Br J Haematol 188:501\u2013510","journal-title":"Br J Haematol"},{"key":"2887_CR22","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1080\/14737140.2017.1330153","volume":"17","author":"S Maharaj","year":"2017","unstructured":"Maharaj S, Chang S, Seegobin K et al (2017) Increased risk of arterial thromboembolic events with combination lenalidomide\/dexamethasone therapy for multiple myeloma. Expert Rev Anticancer Ther 17:585\u2013591","journal-title":"Expert Rev Anticancer Ther"},{"key":"2887_CR23","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/hon.2340","volume":"35","author":"GY Lee","year":"2017","unstructured":"Lee GY, Lee YT, Yeh CM et al (2017) Risk of stroke in patients with newly diagnosed multiple myeloma: a retrospective cohort study. Hematol Oncol 35:726\u2013733","journal-title":"Hematol Oncol"},{"key":"2887_CR24","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s00277-012-1506-2","volume":"91","author":"S-Y Wu","year":"2012","unstructured":"Wu S-Y, Yeh Y-M, Chen Y-P et al (2012) Low incidence of thromboembolism in relapsed\/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan. Ann Hematol 91:1773\u20131778","journal-title":"Ann Hematol"},{"key":"2887_CR25","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/bjh.14465","volume":"176","author":"J Lu","year":"2017","unstructured":"Lu J, Lee JH, Huang SY et al (2017) Continuous treatment with lenalidomide and low-dose dexamethasone in transplant\u2010ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial. Br J Haematol 176:743\u2013749","journal-title":"Br J Haematol"},{"key":"2887_CR26","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/bjh.13942","volume":"176","author":"R Raghupathy","year":"2017","unstructured":"Raghupathy R, Ayyappan S, Prabhakar D et al (2017) Retrospective study of the incidence and patterns of arterial and venous thrombosis in chinese versus african american patients with multiple myeloma. Br J Haematol 176:315","journal-title":"Br J Haematol"},{"key":"2887_CR27","unstructured":"Taiwan Cancer Registry (2021) http:\/\/tcr.cph.ntu.edu.tw\/main.php?Page=N1. Accessed 30"},{"key":"2887_CR28","unstructured":"National Health Insurance Research Database. https:\/\/www.nhi.gov.tw\/English\/Content_List.aspx?n=46A1D826CE8E2F58&topn=ED4A30E51A609E49. Accessed 30 July, 2021"},{"key":"2887_CR29","doi-asserted-by":"publisher","first-page":"4209","DOI":"10.1002\/sim.8320","volume":"38","author":"S Schneeweiss","year":"2019","unstructured":"Schneeweiss S, Suissa S (2019) Discussion of Schuemie et al:a plea to stop using the case-control design in retrospective database studies. Stat Med 38:4209\u20134212","journal-title":"Stat Med"},{"key":"2887_CR30","first-page":"373","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Clin Epidemiol 40:373\u2013383","journal-title":"J Clin Epidemiol"},{"key":"2887_CR31","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM et al (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173:676\u2013682","journal-title":"Am J Epidemiol"},{"key":"2887_CR32","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1023\/A:1011132808904","volume":"12","author":"M Dimopoulos","year":"2001","unstructured":"Dimopoulos M, Zervas K, Kouvatseas G et al (2001) Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 12:991\u2013995","journal-title":"Ann Oncol"},{"key":"2887_CR33","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s12185-018-2540-1","volume":"109","author":"J Shin","year":"2019","unstructured":"Shin J, Lee J-J, Kim K et al (2019) Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone. Int J Hematol 109:79\u201390","journal-title":"Int J Hematol"},{"key":"2887_CR34","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/sj.leu.2405062","volume":"22","author":"A Palumbo","year":"2008","unstructured":"Palumbo A, Rajkumar S, Dimopoulos M et al (2008) Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma. Leukemia 22:414\u2013423","journal-title":"Leukemia"},{"key":"2887_CR35","doi-asserted-by":"crossref","unstructured":"Baz R, Li L, Kottke-Marchant K et al (2005) The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clinic Proceedings 80:1568\u20131574","DOI":"10.4065\/80.12.1568"},{"key":"2887_CR36","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/ajh.25459","volume":"94","author":"B Pegourie","year":"2019","unstructured":"Pegourie B, Karlin L, Benboubker L et al (2019) Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study. Am J Hematol 94:635\u2013640","journal-title":"Am J Hematol"},{"key":"2887_CR37","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/pds.4180","volume":"26","author":"A Palmaro","year":"2017","unstructured":"Palmaro A, Roug\u00e9-Bugat ME, Gauthier M et al (2017) Real\u2010life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the french health insurance database. Pharmacoepidemiol Drug Saf 26:578\u2013586","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2887_CR38","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.thromres.2008.09.008","volume":"123","author":"KM Musallam","year":"2009","unstructured":"Musallam KM, Dahdaleh FS, Shamseddine AI et al (2009) Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy. Thromb Res 123:679\u2013686","journal-title":"Thromb Res"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-023-02887-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-023-02887-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-023-02887-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T11:05:21Z","timestamp":1696417521000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-023-02887-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,22]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["2887"],"URL":"https:\/\/doi.org\/10.1007\/s11239-023-02887-7","relation":{},"ISSN":["1573-742X"],"issn-type":[{"type":"electronic","value":"1573-742X"}],"subject":[],"published":{"date-parts":[[2023,9,22]]},"assertion":[{"value":"12 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}